Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVABN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania
Anywaine Z et al.
The Journal of Infectious Diseases 2019 Jun 5;220(1):46-56.
Safety, immunogenicity and risk–benefit analysis of rVSV- G-ZEBOV-GP (V920) Ebola vaccine in Phase I–III clinical trials across regions
Bache Emmanuel Bache, Martin P Grobusch & Selidji Todagbe Agnandji
Future Microbiology 2020;12(2):85-106.
Ebola virus vaccine receives prequalification
The Lancet 2019; 394.
Vaccination of contacts of Ebola virus disease survivors to prevent further transmission
The Lancet Global Health Dec 2020; 8.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV
Nature Medicine 2019 Oct;25,1589–1600.
Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Ad26- and MVA-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
The Journal of Infectious Diseases 2020; jiaa586.